Literature DB >> 14645120

Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.

Sheng-Nan Wu1, Shiuh-Inn Liu, Mei-Han Huang.   

Abstract

The effects of cilostazol, a dual inhibitor of type 3 phosphodiesterase and adenosine uptake, on ion currents were investigated in pituitary GH(3) cells and pheochromocytoma PC12 cells. In whole-cell configuration, cilostazol (10 microm) reversibly increased the amplitude of Ca(2+)-activated K(+) current [I(K(Ca))]. Cilostazol-induced increase in I(K(Ca)) was suppressed by paxilline (1 microM) but not glibenclamide (10 microm), dequalinium dichloride (10 microM), or beta-bungarotoxin (200 nM). Pretreatment of adenosine deaminase (1 U/ml) or alpha,beta-methylene-ADP (100 microM) for 5 h did not alter the magnitude of cilostazol-stimulated I(K(Ca)). Cilostazol (30 microM) slightly suppressed voltage-dependent l-type Ca(2+) current. In inside-out configuration, bath application of cilostazol (10 microM) into intracellular surface caused no change in single-channel conductance; however, it did increase the activity of large-conductance Ca(2+)-activated K(+) (BK(Ca)) channels. Cilostazol enhanced the channel activity in a concentration-dependent manner with an EC(50) value of 3.5 microM. Cilostazol (10 microM) shifted the activation curve of BK(Ca) channels to less positive membrane potentials. Changes in the kinetic behavior of BK(Ca) channels caused by cilostazol were related to an increase in mean open time and a decrease in mean closed time. Under current-clamp configuration, cilostazol decreased the firing frequency of action potentials. In pheochromocytoma PC12 cells, cilostazol (10 microM) also increased BK(Ca) channel activity. Cilostazol-mediated stimulation of I(K(Ca)) appeared to be not linked to its inhibition of adenosine uptake or phosphodiesterase. The channel-stimulating properties of cilostazol may, at least in part, contribute to the underlying mechanisms by which it affects neuroendocrine function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645120     DOI: 10.1210/en.2003-1430

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  Potassium channels: a review of broadening therapeutic possibilities for neurological diseases.

Authors:  Snezana Maljevic; Holger Lerche
Journal:  J Neurol       Date:  2012-11-11       Impact factor: 4.849

Review 2.  Targeting BKCa Channels in Migraine: Rationale and Perspectives.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Christian Gram; Cherie Amalie Waldorff Nielsen; Messoud Ashina
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

3.  Effective Activation of BKCa Channels by QO-40 (5-(Chloromethyl)-3-(Naphthalen-1-yl)-2-(Trifluoromethyl)Pyrazolo [1,5-a]pyrimidin-7(4H)-one), Known to Be an Opener of KCNQ2/Q3 Channels.

Authors:  Wei-Ting Chang; Sheng-Nan Wu
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

4.  Permissive Modulation of Sphingosine-1-Phosphate-Enhanced Intracellular Calcium on BKCa Channel of Chromaffin Cells.

Authors:  Adonis Z Wu; Tzu-Lun Ohn; Ren-Jay Shei; Huei-Fang Wu; Yong-Cyuan Chen; Hsiang-Chun Lee; Dao-Fu Dai; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

5.  The role of cilostazol, a phosphodiesterase 3 inhibitor, on oocyte maturation and subsequent pregnancy in mice.

Authors:  Min Li; Yang Yu; Jie Yan; Li-Ying Yan; Yue Zhao; Rong Li; Ping Liu; Aaron J Hsueh; Jie Qiao
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

Review 6.  Cilostazol: a Review of Basic Mechanisms and Clinical Uses.

Authors:  Riyad Y Kherallah; Muzamil Khawaja; Michael Olson; Dominick Angiolillo; Yochai Birnbaum
Journal:  Cardiovasc Drugs Ther       Date:  2021-04-16       Impact factor: 3.947

Review 7.  BK channel activators and their therapeutic perspectives.

Authors:  Bo H Bentzen; Søren-Peter Olesen; Lars C B Rønn; Morten Grunnet
Journal:  Front Physiol       Date:  2014-10-09       Impact factor: 4.566

8.  High Efficacy by GAL-021: A Known Intravenous Peripheral Chemoreceptor Modulator that Suppresses BKCa-Channel Activity and Inhibits IK(M) or Ih.

Authors:  Te-Ling Lu; Zi-Han Gao; Shih-Wei Li; Sheng-Nan Wu
Journal:  Biomolecules       Date:  2020-01-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.